Leadership
Our board and management are as dedicated as our employees to drive Mabtech forward. A key feature is the efficient collaboration across all of our departments, facilitated by a shared view on customer satisfaction.
Management
Phill Keefe
Chief Executive Officer
phill.keefe@mabtech.com
Phill joined Mabtech in February 2025 and brings over 30 years of valuable industry experience. Phill has held a wide range of senior leadership positions across multiple global organisations, most recently as CEO of Oxford Immunotec.
Torun Ekblad, PhD
Chief Operating Officer
torun.ekblad@mabtech.com
Holds a PhD in biotechnology from the Royal Institute of Technology in Stockholm, with a postdoc at the Karolinska Institute. Joined Mabtech and the R&D team in 2016 and was appointed COO in 2018.
Bartek Makower, PhD
Chief Scientific Officer
bartek.makower@mabtech.com
Holds a PhD in virology and immunology from the Karolinska Institute. Joined Mabtech and the R&D team 2002 and left for a Senior Scientist role at Swedish Orphan Biovitrum in 2015. Re-joined Mabtech as CSO in 2018.
Jens Gertow, PhD
Chief Commercial Officer
jens.gertow@mabtech.com
Holds a PhD in transplantation immunology from the Karolinska Institute, where he also did a postdoc at the Department of Medicine. Joined Mabtech in 2015 and was appointed CCO in 2018.
Catarina Pinho, PhD
Head of Quality and Regulatory Affairs
catarina.pinho@mabtech.com
Holds a PhD in Biochemistry from Stockholm University, with a postdoc at the Karolinska Institute. Before joining Mabtech, Catarina held various roles in R&D, Quality and Regulatory affairs within in vitro diagnostics companies. Joined Mabtech as Head of Quality and Regulatory Affairs in 2024.
Christian Smedman, PhD
Chief Technology Officer
christian.smedman@mabtech.com
Holds a PhD in immunology from the Karolinska Institute (a joint Industrial PhD program between Mabtech and the Karolinska Institute). Joined Mabtech as Head of Sales & Marketing in 2013 and was appointed Chief Technology Officer and Head of IT in 2018.
Kimberlee Parent
Head of USA
kimberlee.parent@mabtech.com
Prior to joining Mabtech Kim was General Manager at Quanterix and prior to that was Head of Sales NA at MilliporeSigma. Kim holds a BS in Molecular & Cell Biology and spent 5 years in Tim Springer's lab at The Center For Blood Research, now Immune Disease Institute in Boston.
Thomas Stals, MSc
Head of Strategy
thomas.stals@mabtech.com
Thomas has been the Head of Strategy since January 2025. Before joining Mabtech, he served as a Project Leader at BCG, focusing primarily on the intersection of private equity and healthcare. He holds an MSc in Biomedical Engineering from the Catholic University of Leuven.
Jonas Winberg, MSc
Chief Financial Officer
jonas.winberg@mabtech.com
CFO at Mabtech since November 2024. Prior to joining Mabtech Jonas was Group CFO and EVP Common functions at Iver Group, a Nordic full service IT provider. Jonas has several years of experience within high growth Nordic leveraged assets with multiple PE players.
Board
Lars Rasmussen
Chairman of the board
Chair of Coloplast & Lundbeck. Chair of the Life Science Council established by the Danish Government, Ex Chair of Lima and Igenomix (both formally EQT owned).
Isabel De Paoli
Partner EQT Healthcare Growth
Isabel joined EQT Partners in September 2021 based in Munich. Isabel worked almost 15 years for Merck KGaA. Lately as Chief Strategy Officer of Merck, she focused on long term portfolio, capital allocation and innovation strategies in the Pharmaceuticals and Life Science space as well as on transformation topics. Prior to that, Isabel has been with Permira and with The Boston Consulting Group. Isabel holds an M.Sc. degree in Process Engineering, with focus on Biotech, from the Technical University Hamburg-Harburg and a B.Sc. in Chemical Engineering from UNICAMP, Brazil.
Klaus-Reinhard Bischoff
Member of the board
Ex Head of Research Solutions at MilliporeSigma; the life science business of Merck, EVP Americas of Laboratory Business at Merck, and EVP of Lab Solutions at Merck.
Mark Braganza
Partner EQT Healthcare Growth
Mark has Physiology and Medical degrees from the University of Cambridge. He led the development of diagnostics for stratification of cancer patients at Chiron Corp until its acquisition by Novartis. Mark has been an investor in healthcare and lifesciences companies since 2006 and is a Partner in the EQT Healthcare Growth advisory team.
Harry Klagsbrun
Member of the board
Holds a B.A. in Journalism from Stockholm University, a M.Sc. in Business from the Stockholm School of Economics and an MBA from New York University. He has over 40 years of international experience as an advisor, investor and owner, with specialist expertise in corporate governance, corporate culture, company transformation and value creation, most recently from 15 years at EQT. Harry joined the Mabtech board in April 2024.
Peter Wrighton-Smith
Member of the board
Holds a PhD in Medical Engineering from the University of Oxford and works as an independent advisor, director and investor in Life Science companies. Previously CEO of Oxford Immunotec (NASDAQ:OXFD) a T-cell immunology based diagnostics company and currently Member of the Board of Directors of biomodal and natcap.